Crinetics Pharmaceuticals shares rise 1.02% after-hours after receiving FDA Orphan Drug Designation for atumelnant.

Crinetics Pharmaceuticals, Inc. rose 1.02% in after-hours trading, following the news that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). The company reported robust positive topline results from the Phase 2 TouCAHn trial of atumelnant in adults with classic CAH, demonstrating substantial, rapid, and sustained reductions of key biomarkers across doses.